COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL MOTILITY DYSFUNCTION
Extended release oral dosage forms for the treatment of gastrointestinal motility disorders are described. Active agents which are small molecules, peptides, peptide analogs, and peptide mimetics are formulated for optimal release in the GI tract of subjects with GI motility dysfunction. Methods of treatment using the dosage forms are also described.
1 . An extended release oral dosage form comprising a therapeutically effective amount of an active agent for the treatment of a gastric motility disorder.
2 . The dosage form of claim 1 , where the active agent is selected from the group consisting of 5-HT4 receptor modulators, dopamine receptor antagonists, growth hormone secretagogue receptor modulators, and motilin receptor modulators.
3 . The dosage form of claim 1 , wherein the extended release dosage form comprises a gastric retained dosage form.
4 . The dosage form of claim 1 , wherein the extended release dosage form comprises an osmotic pump.
5 . The dosage form of claim 1 , which further comprises a buffering agent.
6 . The dosage form of claim 1 , which further comprises an antioxidant.
7 . The dosage form of claim 1 , wherein the active agent is contained in the dosage form as enteric-coated particles or enteric-coated micropellets.
8 . The dosage form of claim 1 , wherein the active agent is a growth hormone secretagogue agonist.
9 . An extended release oral dosage form comprising a therapeutically effective amount of an active agent which promotes gastric emptying, wherein the dosage form remains in the stomach of a patient for about 2 to about 10 hours, and provides extended release of the active agent.
10 . The dosage form of claim 9 , wherein the active agent is selected from the group consisting of 5-HT4 receptor modulators, dopamine receptor antagonists, growth hormone secretagogue receptor modulators, and motilin receptor modulators.
11 . A method of treating a gastric motility disorder comprising providing the dosage form of claim 1 for administration to a subject in need of treatment. 12 , The method according to claim 11 , wherein the gastric motility disorder is gastroparesis.